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Background: Asthma is a complex disease influenced by multiple genetic and environmental factors. While
Madeira has the highest prevalence of asthma in Portugal (14.6%), the effect of both genetic and environmental
factors in this population has never been assessed. We categorized 98 asthma patients according to the Global
Initiative for Asthma (GINA) guidelines, established their sensitization profile, and measured their forced expiratory
volume in 1 second (FEV1) and forced vital capacity (FVC) indexes. Selected single nucleotide polymorphisms (SNPs)
were analysed as potential markers for asthma susceptibility and severity in the interleukin 4 (IL4), interleukin 13
(IL13), beta-2-adrenergic receptor (ADRB2), a disintegrin and metalloprotease 33 (ADAM33), gasdermin-like (GSDML)
and the signal transducer and activator of transcription 6 (STAT6) genes comparatively to a population reference set.
Results: Although mites are the major source of allergic sensitization, no significant difference was found amongst
asthma severity categories. IL4-590*CT/TT and IL4-RP2*253183/183183 were found to predict the risk (2-fold) and
severity (3 to 4-fold) of asthma and were associated with a lower FEV1 index. ADRB2-c.16*AG is a risk factor (3.5-fold),
while genotype GSDML-236*TT was protective (4-fold) for moderate-severe asthma. ADAM33-V4*C was associated to
asthma and mild asthma by the transmission disequilibrium test (TDT). Finally, ADAM33-V4*CC and STAT6-21*TT were
associated with higher sensitization (mean wheal size ≥10 mm) to house dust (1.4-fold) and storage mite (7.8-fold).
Conclusion: In Madeira, IL4-590C/T, IL4-RP2 253/183, GSDML-236C/T and ADAM33-V4C/G SNPs are important risk
factors for asthma susceptibility and severity, with implications for asthma healthcare management.
Keywords: Asthma, Madeira, SNPs, Susceptibility, SeverityBackground
Asthma is a chronic airway inflammation, characterized
by variable airway obstruction and reduced lung func-
tion, and leading to wheezing and shortness of breath
[1]. It is described as a complex disease arising from
the contribution of multiple genetic and environmen-
tal factors [2,3], affecting more than 300 million
people worldwide, with increased prevalence in devel-
oped societies [4].* Correspondence: anabela.berenguer@oulu.fi
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article, unless otherwise stated.In Portugal, 7.83% of the population is affected by
clinical asthma and 8.72% by wheezing symptoms [5].
Within Portugal, the island of Madeira has a high
prevalence of the disease, as active asthma (presence of
symptoms during the last 12 months) affects 14.6%,
and atopy (positive reaction to skin prick tests (SPT) to
common aeroallergens and the presence of specific IgE)
affects 54% of the population [6].
Given the high prevalence of asthma in the Madeira
population [6], determining the population’s genetic
background is an essential first step towards understanding
the mechanisms of the disease. In previous work [7]
we showed that both IL4-590 and IL4-RP2 are useful
genetic markers to detect asthma predisposition in the
Madeira population. Investigating a larger number oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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rather than just a few with strong effects, contribute to the
disease risk [8]. A useful clustering of asthma susceptibility
genes has been proposed [9]: i) triggers of the immune re-
sponse (such as CD14, IL10, STAT3, MHC class II mole-
cules); ii) regulators of the T helper 2 (Th2) differentiation
(IL12B, IL4, IL13, STAT6, IL4RA); iii) associated with
epithelial biology (CCL5, FLG, SPINK5, GSDML) and iv)
linked to lung function, airway remodeling and asthma
severity (ADRB2, ADAM33, DPP10, PHF11).
Here we extend our analysis in four important ways,
to consider i) 6 additional polymorphisms, namely
IL13-c.144 G/A, ADRB2-c.16 A/G, ADAM33-V4 C/G,
ADAM33-S1 c.710 G/A, GSDML-236 C/T and STAT6-21
C/T (guided by a literature review summarized in Table 1),
ii) the asthma persistence and severity classes according
to GINA guidelines, iii) the most common allergens in
the island and iv) the FEV1/FVC lung function indexes.
Therefore, this work contributes to the analysis of the
association of the above polymorphisms to asthma suscep-
tibility and severity, FEV1/FVC indexes and sensitization
profiles, in the Madeira population.
Results
Demographic and clinical characterization of the asthmatics
The demographic and clinical characterization of the
asthmatic population analysed in this study are shown in
Table 2. The patients’ mean age was 13.6 ± 4.3 years old,
with 59.2% males. None of the asthma persistence or sever-
ity phenotypes was found sub-structured by the male-to-
female ratio. The FEV1 and FVC indexes were significantly
different between mild persistent and moderate-severe
persistent asthma (Mean FEV1 t = 2.732, p-value = 0.008;
FVC Mann–Whitney U = 456.0, p-value = 0.025).
Although persistent asthmatics were found more fre-
quently sensitized to both cat and dog allergen than
intermittent asthmatics (Additional file 1) no signifi-
cant differences were observed for SPT positivity or
degree of sensitization to the most common allergens
in the island, namely dust and storage mites mix fungi,
indoor fungi, cat or dog.Table 1 Selected studies previously reporting association of t
Gene Polymorphism dbSNP rs ref (NCBI) Chrom
IL13 c.144Gln/Arg rs20541 5q31 e
IL4 590 rs2243250 5q31 p
IL4 RP2 - 5q31 in
ADRB2 c.16Arg/Gly rs1042713 5q31 e
ADAM33 V4 rs2787094 20p13
ADAM33 S1 c.710Val/Ile rs3918396 20p13
GSDML 236 rs7216389 17q21
STAT6 21 rs324011 12q13-SNP association to asthma risk and severity
The genotypic and allelic frequencies of each SNP among
asthma subgroups and population reference set are de-
scribed in Table 3 and Additional file 2, respectively. The
genotypic distribution of SNPs in controls reflects previ-
ously published data on other European and Mediterranean
populations [45,46]. All SNP polymorphisms were found to
be in HWE, except for STAT6-21 locus in mild persistent
asthma (p-value = 0.038). Nevertheless, this SNP was
considered in the analysis under a more stringent p-value
cut-off of 0.01, since a slight deviation from HWE is
allowed for SNPs linked to disease status [47].
Table 3 shows significant effects for the genotypes
IL4-590*CT/TT, IL4-RP2*183253/183183, ADRB2-c.16*AG/
AA, and GSDML-236*TT. Specifically, the IL4-590*CT/TT
genotypes were significantly more frequent in asthma
patients (35.8% vs. 20.0%, χ2 p-value = 0.009; OR 2.222,
95% CI 1.191-4.146), persistent asthma (37.8% vs. 20.0%;
χ2 p-value = 0.006; OR 2.433, 95% CI 1.264-4.717), and
moderate-severe asthma vs. the reference set (20% vs.
50.0%; χ2 p-value = 0.002; OR 4.000, 95% CI 1.701-9.434).
Genotypes IL4-RP2*183253/183183 were significantly
more frequent in asthma patients (30.7% vs. 18.2%; χ2
p-value = 0.027; OR 1.984, 95% CI 1.040-3.788), in persist-
ent asthma (33.8% vs. 18.2%; χ2 p-value = 0.013; OR 2.296,
95% CI 1.159-4.547), and in the moderate-severe asthma
vs. the reference set (46.7% vs. 18.2%; χ2 p-value = 0.002;
OR 3.938, 95% CI 1.657-9.357). ADRB2-c.16*AG was sig-
nificantly more frequent in moderate-severe asthma vs.
mild asthma (66.7% vs. 36.4%, p-value = 0.010, OR 3.500,
95% CI 1.318-9.293) while GSDML-236*TT displays a sig-
nificant opposite trend (20.0% and 50.0%, respectively in
moderate-severe and mild asthma; χ2 p-value = 0.008, 0R
0.250 95% CI 0.086-0.730).
The results described above are corroborated by the
allelic counts (Additional file 2) of IL4-590*T, which
are significantly higher in asthma patients (19.4%; χ2
p-value = 0.010, OR 2.060, 95% CI 1.178-3.601), in
persistent asthma (20.3% χ2 p-value = 0.009, OR 2.178
95% CI 1.208-3.925), and in moderate-severe (28.3%,
χ2 p-value = 4.514*10−4, OR 3.386 95% CI 1.668-6.877)he studied SNPs and asthma
osome location Alleles (ancestral:derived) References
xon 4 G > A [10-16]
romoter C > T [17-23]
tron 2 253 > 183(del) [24]
xon A > G [25,26]
3’UTR C > G [27-30]
exon 19 G > A [27]
intron 1 C > T [31-39]
24 intron 2 C > T [19,40-44]
Table 2 Clinical characterization of the asthmatics study population
Study sample set
Overall asthma Intermittent asthma Persistent asthma Mild Moderate-severe p-value
Sample size (n,%) 98 (100.0) 24 (24.5) 74 (75.5) 44 (59.9) 30 (40.5)
Male/Female (%) 59.2/40.8 62.5/37.5 58.1/41.9 54.5/45.5 63.3/36.7
Mean age (years + −s.d.) 13.6 + −4.3 14.1 + −3.5 13.4 + − 4.5 14.3 + −4.6 12.0 + − 4.1
Mean FEV1 (%) 96.9 + −14.7 98.5 + −16.3 96.4 + −14.2 99.9 + −10.7 91.2 + − 17.1 0.008
Mean FVC (%) 95.0 + −12.8 97.4 + −12.1 94.3 + −13.0 97.3 + −9.9 89.8 + −15.6 0.025
Asthma classification according to GINA [75].
A Shapiro-Wilk test showed that FEV1 is normally distributed (p > 0.05) while FVC is not (p = 0.008). Thus, a t-test was used for the analysis of FEV1 while a
Mann–Whitney test was used for FVC. Statistically significant p-values were found for comparisons between mild persistent and moderate-severe persistent
asthma, denoted in bold.
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IL4-RP2*183 were significantly higher in moderate-severe
vs. the reference set (26.7% vs. 10.5%; χ2 p-value = 0.001,
OR 3.115 95% CI 1.521-6.379).
SNP association to FEV1 and FVC
Table 4 shows the association analysis of SNP genotypes
with the FEV1 and FVC indexes. Significant differences were
found for mean FEV1 distribution among IL4-590*C/T ge-
notypes (F = 3.982, p-value = 0.024), with IL4-590*CT/TT
patients exhibiting a significantly lower FEV1 values when
compared to IL4-590*CC homozygotes patients (t = 2.797,
p-value = 0.006). Similarly, a significantly lower FEV1 index
was found amongst patients with IL4-RP2*183253/183183
when compared to IL4-RP2*253253 homozygotes (t = 2.974,
p-value = 0.004).
SNP association to SPT
Despite not associated to SPT positivity, some of
the studied SNPs relate to the sensitization degree
(Table 5). ADAM33-V4*CC relates to house dust mite
(Dermatophagoides pteronyssinus χ2 p-value = 0.016,
OR 1.325, 95% CI 1.070-1.641 and Blomia tropicalis χ2
p-value = 0.047, OR 1.355, 95% CI 1.131-1.622). STAT6-
21*TT is associated to the degree of sensitization for storage
mite (χ2 p-value = 0.003, OR 7.778, 95% CI 1.682- 35.962).
SNP haplotypes and epistasis association to asthma risk
Table 6 shows the haplotype frequencies for SNPs at the
5q31 and 20p13 chromosomal regions. At the 5q31, we
highlight IL4-590/IL4-RP2* T183 frequency, which is
significantly lower in the reference set (8.8%) than
overall asthma (16.8%, p-value = 0.019), persistent
asthma (18.2%, p-value = 0.011), and moderate-severe
asthma (26.7%, p-value = 3×10−4). In addition, this same
haplotype was more common in moderate-severe vs. mild
asthma (26.7% vs. 12.5%, p-value = 0.029). In fact, every
haplotype found to associate with the risk of asthma in-
cludes either IL4-590 C/T or IL4-RP2183/253 or both.
Compared to the reference set, the most significant
combinations are i) overall asthma IL13c.144/IL4-590*GT(p-value = 0.018); ii) persistent asthma IL13c.144/IL4-
590*GT (p-value = 0.010) and iii) moderate-severe asthma
IL4-590/IL4-RP2*T183 (p-value = 3x10−4). IL13c.144/IL4-
RP2*A183 is also more frequently found in moderate-
severe asthma than in mild asthma (p-value = 0.017).
Epistatic interactions between pairs of SNPs between all
asthma subgroups were tested, revealing significant epista-
sis for loci IL4-590 and STAT6-21 in moderate-to-severe
compared to intermittent asthma (p-value = 0.044) and
IL13-c.144 and ADAM33-V4 between persistent asthma
and the Madeira reference set (p-value = 0.035).
TDT association analysis
The TDT analysis in Table 7 suggests that the ADAM33-
V4*C allele is significantly over transmitted to offsprings in
overall asthma (ratio 27/15 of transmitted/non-transmitted;
McNemar χ2 3.429, p-value = 0.044, OR 1.800, 95% CI
0.956-3.384), in persistent asthma (ratio 22/9 of transmitted/
non-transmitted; McNemar χ2 5.452, p-value = 0.015
OR 2.444, 95% CI 1.126-5.309), and in mild asthma
(ratio 16/4 of transmitted/non-transmitted; McNemar
χ2 7.200 p-value = 0.006 OR 4.000, 95% CI 1.337-11.965).
IL4-590*T and IL4-RP2*183 alleles were found to be sig-
nificantly over transmitted only amongst moderate-severe
offspring asthma (ratio 15/6 of transmitted/non-transmitted;
McNemar χ2 3.857, p-value = 0.039 OR 2.500, 95% CI
0.970-6.443 and ratio 14/4 of transmitted/non-transmitted;
McNemar χ2 5.556, p-value = 0.015 OR 3.500, 95% CI
1.152-10.663, respectively).
Discussion
In the asthmatic patients studied, 24.5% are classified as
intermittent asthmatics while the remaining are persist-
ent asthmatics (of which 40.5% show moderate-severe
forms of the disease). The significant differences we ob-
served for FEV1 and FVC indexes denote these as reli-
able indicators for disease severity, as previous stated by
a number of studies [48-50].
SNP IL4-590 C/T has been repeatedly associated to
asthma in several population backgrounds [17-22] and
the results of this study in the Madeira island population
Table 3 SNP genotypic frequencies for the Madeira reference set and asthmatics study population
SNP genotypes Study sample set
Madeira reference set Overall asthma Intermittent asthma Persistent asthma Mild Moderate-severe
105a 98 24 74 44 30
IL4-590 C/T
CC 0.800 0.643 0.708 0.622 0.705 0.500
CT 0.191 0.327 0.250 0.351 0.295 0.433
TT 0.009 0.031 0.042 0.027 0 0.067
p-value 0.009 0.006 0.002
OR (95%CI) 2.222 (1.191-4.146) 2.433 (1.264-4.717) 4.000 (1.701-9.434)
IL4-RP2 253/183
253253 0.818 0.694 0.792 0.662 0.750 0.533
183253 0.155 0.276 0.167 0.311 0.250 0.400
183183 0.027 0.031 0.042 0.027 0 0.067
p-value 0.027 0.013 0.002
OR (95%CI) 1.984 (1.040 -3.788) 2.296 (1.159 -4.547) 3.938 (1.657- 9.357)
IL13-c.144 G/A
GG 0.676 0.704 0.625 0.730 0.773 0.667
GA 0.305 0.267 0.333 0.257 0.205 0.333
AA 0.019 0.020 0.042 0.014 0.023 0
ADRB2-c.16 A/G
AA 0.181 0.194 0.250 0.176 0.250 0.067
AG 0.457 0.480 0.458 0.486 0.364 0.667
GG 0.362 0.327 0.292 0.338 0.386 0.267
p-value 0.010*
OR (95%CI) 3.500 (1.318-9.293)
ADAM33-V4 C/G
GG 0.029 0.010 0 0.014 0.023 0
CG 0.209 0.235 0.292 0.216 0.182 0.267
CC 0.762 0.755 0.708 0.770 0.795 0.733
ADAM33-S1c.710
G/A GG 0.905 0.929 0.917 0.932 0.932 0.933
GA 0.095 0.071 0.083 0.068 0.068 0.067
AA 0 0 0 0 0 0
GSDML-236 C/T
CC 0.171 0.163 0.167 0.162 0.136 0.200
CT 0.467 0.469 0.500 0.459 0.364 0.600
TT 0.362 0.367 0.333 0.378 0.500 0.200
p-value 0.008**
OR (95%CI) 0.250 (0.086-0.730)
STAT6-21 C/T b
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Table 3 SNP genotypic frequencies for the Madeira reference set and asthmatics study population (Continued)
CC 0.428 0.449 0.417 0.459 0.523 0.367
CT 0.486 0.418 0.458 0.405 0.295 0.567
TT 0.086 0.133 0.125 0.135 0.182 0.067
a) Except for IL4-590 and IL4-RP2 (n = 110);
b) Polymorphism not in HWE for mild asthma (p-value = 0.038).
χ2 (or Fisher’s exact test when appropriate) significant p-values and OR (95%CI), using the Madeira reference set as a control, are shown in bold (dominant model).
* Heterozygote model, significant p-values and OR (95%CI) for comparison between mild persistent and moderate-severe persistent; Dominant model, Fisher’s
exact test p-value = 0.038, OR (95%CI) 4.667 (0.953-22.851); ** Recessive model, significant p-values and OR (95%CI) for comparison between mild persistent and
moderate-severe persistent; Heterozygote model: Fisher’s exact test p-value = 0.039, OR 2.625 (1.011-6.817).
Table 4 Mean FEV1 and FVC indexes across SNP genotypes
SNP genotypes Lung function indexes
FEV1 (mean +/−s.d.) FVC (mean+/−s.d.)
n 98 98
IL13-c.144 G/A GG 98.42 + −13.95 96.33 + −11.88
GA 93.44 + −16.58 92.15 + −14.79
AA 92.50 + −7.78 89.50 + −12.02
IL4-590 C/T CC 99.92 + −14.28 96.87 + −11.28
CT 91.69 + −14.41 92.13 + −14.79
TT 90.00 + −12.00 87.67 + 16.04
F p-value 0.024
Dominant model CT/TT vs CC 0.006
IL4-RP2 253/183 253253 99.75 + −14.15 97.07 + −11.34
183253 90.59 + −14.52 90.74 + −14.89
183183 90.00 + −12.00 87.67 + −16.04
F p-value 0.015
Dominant model 183253/183183 vs 253253 0.004
ADRB2-c.16 A/G AA 95.16 + −19.79 91.74 + −16.20
AG 95.91 + −12.83 94.91 + −11.95
GG 99.47 + −13.94 97.19 + −11.62
ADAM33-V4 C/G GG 99.00 + −0 c 98.00 + −0c
CG 94.65 + −15.66 94.26 + −10.19
CC 97.61 + −14.53 95.24 + −13.61
ADAM33-S1c.710 G/A GG 97.13 + −14.81 95.22 + −13.05
GA 94.29 + −13.96 92.71 + −8.92
AA - -
GSDML-236 C/T CC 99.13 + −13.20 94.25 + −12.07
CT 96.30 + −17.48 94.13 + −14.34
TT 96.75 + −11.34 96.56 + −11.04
STAT6-21 C/T CC 97.34 + −15.74 95.00 + −14.28
CT 96.49 + −13.52 94.24 + −11.73
TT 96.92 + −15.73 97.69 + −11.01
c n = 1.
A Shapiro-Wilkoxon test showed that FEV1 is normally distributed (p > 0.05) while FVC is not (p = 0.008). Thus, ANOVA was used for FEV1 analysis while a
Kruskal-Wallis test was used for FVC.
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Table 5 Skin prick tests positivity across SNP genotypes
Allergen panel SNP genotypes
ADAM33-V4 C/G
n GG CG CC p-value OR (95% CI)
Dermatophagoides pteronyssinus (−) 23 0.043 0.348 0.609
(+) 74 0 0.203 0.797
< 10 mm 44 0 0.295 0.705
≥ 10 mm 30 0 0.067 0.933 0.016 1.325 (1.070-1.641)
Blomia tropicalis (−) 43 0.023 0.279 0.698
(+) 54 0 0.204 0.796
< 10 mm 42 0 0.262 0.738
≥ 10 mm 12 0 0 1.00 0.047 1.355 (1.131-1.622)
STAT6-21 C/T
CC CT TT
Storage mites (−) 53 0.396 0.472 0.132
(+) 44 0.500 0.364 0.236
< 10 mm 35 0.514 0.429 0.057
≥ 10 mm 9 0.444 0.111 0.444 0.003* 7.778 (1.682-35.962)
Only significant associations are reported, in bold.
Storage mites: Lepidoglyphus destructor, Glycifagus domesticus, Acarus siro, Euroglyphus maynei and Tyrophagus putrescentiae allergens, classified as ≥ 10 mm if at
least one test resulted in wheal diameter ≥ 10 mm.*Recessive model.
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search team [7]. Our findings show that IL4-590*CT/
TT genotypes associate to a 2.2-fold risk for asthma
(2.4-fold for overall persistent asthma and 4-fold for
moderate-severe persistent asthma) while IL4-590*T







IL4-590/ IL4-RP2 T183 0.088 0.168 (0.019)
C253 0.894 0.806
IL4-590 /ADRB2-c.16 TA 0.018 0.058 (0.037)
TG 0.092 0.136
IL4-RP2/ADRB2-c.16 183A 0.025 0.057
183G 0.084 0.111
IL13-c.144/ IL4-590 GT 0.064 0.134 (0.018)
AT 0.046 0.060
IL13-c.144/ IL4-RP2 G183 0.059 0.106
A183 0.050 0.063
IL13-c.144/ IL4-590/ IL4-RP2 GT183 0.051 0.107 (0.041)
AT183 0.040 0.062
IL4-590/ IL4-RP2/ ADRB2-c.16 T183A 0.016 0.055 (0.038)
T183G 0.073 0.113
Haplotypes denoting significant differences are shown in bold, with respective p-va
control, are shown within parentheses; * significant p-values for comparison betweepersistent asthma and 3.4-fold for moderate-severe asthma),
compared to individuals harbouring other IL4-590 C/T
genotypes or allele. Our findings also indicate that
IL4-RP2*253183/183183 genotypes translate into a 2-fold
increased risk for asthma (2.3-fold and 2.9-fold respectively







24 74 44 30
0.125 0.182 (0.011) 0.125 0.267 (3x10−4/0.029*)
0.833 0.797 0.852 0.717 (0.004/0.044*)
0.064 0.055 (0.048) 0.031 0.085 (0.009)
0.102 0.148 0.117 0.199 (0.023)
0.059 0.056 0.032 0.089 (0.026)
0.066 0.127 0.093 0.178 (0.037)
0.098 0.146 (0.010) 0.128 0.166 (0.010)
0.068 0.057 0.020 0.110 (0.020*)
0.052 0.124 (0.033) 0.105 0.147 (0.022)
0.073 0.059 0.021 0.114 (0.017*)
0.054 0.125 (0.016) 0.105 0.148 (0.009)
0.071 0.058 0.020 0.119 (0.024/0.018*)
0.052 0.053 (0.045) 0.030 0.082 (0.008)
0.067 0.129 0.095 0.184 (0.013)
lues within parentheses. Significant p-values, using Madeira reference set as a
n mild persistent and moderate-severe persistent.
Table 7 TDT analysis in family trios for SNP association with asthma
SNP allele Valid trios (n) TDT-test value TDT p-value OR (95% CI)
Overall asthma
ADAM33-V4*C 41 3.429 0.044 1.800 (0.956-3.384)
Persistent asthma
ADAM33-V4*C 30 5.452 0.015 2.444 (1.126-5.309)
Mild asthma
ADAM33-V4*C 19 7.200 0.006 4.000 (1.337-11.965)
Moderate-severe asthma
IL4-590*T 19 3.857 0.039 2.500 (0.970-6.443)
IL4-RP2*183 17 5.556 0.015 3.500 (1.152-10.633)
Only significant associations are reported, in bold.
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severe persistent asthma). This SNP has been implicated in
childhood asthma in a Chinese population, where authors
suggest a link between the allele and higher expression of
IL4 in asthma [24]. The findings for IL4 SNPs are further
corroborated by the association of the risk genotypes to
worse lung function, namely lower FEV1 index. Genotype
IL4-590*TT has been previously associated with lower
FEV1 index, used as a measure for asthma severity, in a
population of white asthmatic subjects [51].
IL4 is a key cytokine in IgE production via Th2 pathway
[52], which has been previously shown to play an important
role in asthma pathogenesis [53]. Its serous levels are sig-
nificantly higher in steroid-naive asthmatic children and se-
vere forms of asthma when compared to healthy control
groups [54,55]. From a functional perspective, it is not sur-
prising that IL4 SNPs may regulate its transcription rates:
allele IL4-590*T allows an extra binding site for the nuclear
factor of activated T-cells (NFAT) at IL4 promoter, leading
to a 3-fold higher transcription rate [23]; haplotypes with
IL4-RP2*183 and SNPs within IL4 promoter account for
high IL4 expression [56].
The case–control associations of IL4-590*T and
IL4-RP2*183 to moderate-severe persistent asthma are
further corroborated by TDT analysis (2.5 and 3.5-fold
increased risk respectively). TDT is a family-based test
robust against population stratification [57,58] defined
as the presence of multiple subgroups with distinct allele
frequencies within a population [59]. Although stratification
is mostly noticed in recent history of admixture [60], we
cannot disregard the considerable sub-Saharan and north-
ern African proportion in the Madeira genetic background,
due to the North Atlantic slavetrade on the 16th-19th cen-
turies and previously confirmed by Y-chromosome [61] and
mtDNA studies [62].
Previous studies have related ADRB2-c.16*GG to asthma
onset and severity [25,26]. Conversely, our data suggest
heterozygous ADRB2-c.16*AG as 3.5-fold risk genotype
for moderate-severe asthma. In the absence of functionalstudies, we can only hypothesize that heterodimeric
ADRB2 receptors on the bronchial smooth muscle may
be less stable or bind to a more restricted scope of products
than homodimeric receptors, therefore enhancing more se-
vere forms of asthma. However, the high heterozygosity for
ADRB2-c.16 is found not only in patient’s subgroups but
also in the Madeira reference set and other population sets
[63-65]. Even though it deserves more attention, this may
indicate heterozygote advantage for this SNP or other
in linkage disequilibrium, in a metabolic pathway that
may or may not relate to asthma pathogenesis. Other
examples of heterozygote advantage in ADRB2 exist,
such as ADRB2-c.27*CG that is protective against lung
function decline [66] and accounts for a decreased risk
of asthma [67].
In our data, GSDML-236*TT genotype is found to be a
protective for asthma severity, with a 4-fold significantly
lower frequency in moderate-severe asthma, as opposed
to mild. GSDML-236C/T polymorphism has been related
to asthma predisposition, severity and/or asthma-related
phenotypes in a number of studies [31-39]. However, our
results are in contrast to certain previous studies, which
suggest this genotype is a genetic risk factor for the disease
severity [32,35,37,38]. The GSDML encodes for gasdermin
B protein expressed in epithelial barrier function and
skin differentiation, influencing the expression of the
neighbouring gene ORMDL3 and thus contributing to
asthma susceptibility [34].
The case–control association in our dataset does not
support the influence of ADAM33-V4C/G or ADAM33-
S1c.710G/A in asthma, contrary to some previous work
[27-30] and consistent with other studies [68]. ADAM33-
V4*C allele was nevertheless marginally over transmit-
ted to Madeira asthmatics, as suggested by TDT analysis
(1.8-fold risk for overall asthma, 2.4-fold risk for persist-
ent asthma and 4-fold risk for mild asthma). A similar
trend of association was seen in Caucasian children with
asthma and bronchial responsiveness (p-value = 0.0959)
[27]. Located at 3’-UTR, ADAM33-V4C/G SNP may
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metallopeptidase domain 33 in airway smooth muscle and
lung fibroblasts [27,69,70] thus playing a role on airway
remodeling and bronchial responsiveness [27,71]. In
addition, our study associates ADAM33-V4*CC to a wheal
size ≥ 10 mm both in Dermatophagoides pteronyssinus
and Blomia tropicalis, in accordance with a previous study
relating ADAM33-V4*CC to high levels of IgE against
Blomia tropicalis (Z score: 2.089, p = 0.03) [72].
No significant association with the disease risk was
detected for STAT6-21C/T, similar to the analysis in
[73] but contrary to other studies [19,40-44]. However,
STAT6-21*TT is overrepresented in asthmatics with
a ≥10 mm wheal size reaction to storage mites and
shows a significant epistatic interaction with IL4-590C/T
between moderate-severe persistent and intermittent
asthma. The enhanced allergic response is not unexpected
since STAT6 is a signal transducer and activator of tran-
scription enrolled in the regulation of IgE expression
[40,52,74] whose STAT6-21*T allele promotes higher levels
of IgE [19].
Finally, the haplotype analysis was significant for SNPs
at 5q31, namely IL4-590*T and IL4-RP2*183 in overall
asthma, persistent asthma and moderate-severe persistent
asthma. Haplotypes of IL4-RP2*183 and SNPs within the
promoter of IL4 have been found to account for high IL4
expression [56]. Our results also indicate the synergistic
effect of IL13c.144*G and ADRB2*G with either IL4-590*T
or IL4-RP2*183 or both for the onset of asthma persistent
phenotypes. Nevertheless, their combination equals or
slightly lowers the statistical significance of IL4-590/
IL4-RP2*T183 haplotype in the same classes.
Conclusion
In conclusion, this study has replicated previously reported
genetic associations and brought light to new associations
of polymorphisms, individually or in haplotype, to asthma
susceptibility, persistence and/or severity in the Madeira
island population. IL4-590C/T and IL4-RP2253/183 seem
to play an important role in the development of the dis-
ease, especially its moderate-severe persistent forms, as
demonstrated by allele and haplotype case–control
tests, TDT analysis, and significantly poorer FEV1 index.
GSDML*CT/TT and ADRB2c.16*AG are found to predict
asthma severity in case–control association, respectively
as risk and protective factors for moderate-severe forms.
ADAM33-V4*C and STAT-21*TT seem to enhance the
allergic response to Dermatophagoides pteronyssinus and
Blomia tropicalis and to storages mites, respectively, and
the first is further highlighted by TDT analysis as a risk
factor for mild persistent asthma. The combined genotyp-
ing of IL4-590C/T, IL4-RP2-253/183, GSDML-236C/T and
ADAM33-V4C/G could be of clinical relevance in ascer-
taining the risk of asthma onset and/or its persistence andseverity, thus helping to define appropriate strategies for
asthma healthcare in this island.
Methods
Participants
A sample of 98 atopic asthmatics, aged between 6 and
25 years old, and their parents (fathers n = 88 and mothers
n = 96) were recruited at the Immunoalergology Unit,
Dr. Nélio Mendonça Hospital, in Funchal, Madeira.
For all participants, the last three generations of ancestors
were born and lived in Madeira island. The diagnosis of
asthma was based on clinical criteria associated with
lung function and the SPT. For the epidemiologic
characterization we deployed the ISAAC questionnaire
to the asthmatic population and their parents. Follow-
ing the GINA guidelines [75], pattern and frequency of
symptoms associated with lung function were used to
classify asthma into intermittent (n = 24) and persistent
(n = 74), and the severity in persistent asthma was further
classified as mild (n = 44), moderate (n = 26) and severe
(n = 4). Given the small number of patients, the moderate
and severe subgroups were merged. Asthma induced by
exercise and associated to aspirin was excluded.
Ethics statement
The study had the approval of the Ethics Committee of
Dr. Nélio Mendonça Hospital and the informed consent
of the participants.
Allergy profile
The SPT was tested for an optimized battery with the
most common aeroallergens in this island: house dust
mite (Dermatophagoides pteronyssinus, Blomia tropicalis);
storage mite (Lepidoglyphus destructor, Glycyphagus
domesticus, Acarus siro, Euroglyphus maynei, Tyrophagus
putrescentiae); Mix fungi (Fungus I, Fungus II); indoor
fungi (Aspergillus fumigatus, Mucor sp.) and cat and dog.
STP results were interpreted according to mean wheal size:
positive ≥3 mm, sensitization degree ≤10 mm or ≥10 mm.
DNA extraction and genotyping
Patients’ blood samples were collected by venipuncture
in 8 ml EDTA blood collection tubes and their DNA was
extracted by salting-out method (adapted from [76]).
Their parents contributed with saliva samples, collected
in Oragene•DNA (OG-250) kits (Oragene). The DNA
extraction followed the manufacturer’s instructions.
A sample of 110 unrelated individuals, whose ances-
try was of local origin for the last three generations,
was obtained from the Blood Sample Bank of Human
Genetics Laboratory (LGH) and their DNA extraction
was performed by a standard phenol-chloroform protocol
(adapted from [77]). These constitute the Madeira popula-
tion reference sample set, although their disease status is
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the patient’s group to uphold a less biased study design.
Each SNP (Table 1) was analysed by TaqMan real-time
PCR (Applied Biosystems) according to the manufacturer’s
instructions, in a 7300 System SDS Software v1.4.Statistical analysis
The statistical analysis was performed using SPSS
(IBM SPSS Statistics, version 19.0.0), except for the
Hardy-Weinberg Equilibrium (HWE) for each polymorph-
ism, determined in ARLEQUIN version 3.11 [78]. Gender
and SPT data among subgroups of asthma persistence and
severity were analysed using Fisher’s exact test, to account
for the small sample size.
Following a Shapiro-Wilkoxon test of normality, the
association analysis of FEV1 to asthma persistence and
severity was performed using a t-test (normal distribution),
while a Mann–Whitney test was used for FVC (due to
its non-normal distribution). The analysis of FEV1 and
FVC indexes among SNP genotypes was tested using
ANOVA (with Bonferroni post-hoc correction) and
Kruskal-Wallis test, respectively.
The association of SNP genotypes and alleles to asthma
susceptibility and severity, for multiple genetic models, were
assessed by χ2 (or Fisher’s exact tests where appropriate)
and corresponding odds ratio (OR) determined with a 95%
CI. Haplotypes were generated with Haploview version 4.2
[79] and their association with the disease was analysed
with the hap-assoc option in PLINK [80]. Epistatic interac-
tions between pairs of SNPs were assessed with the PLINK
option –epistasis –epi1 1. Permutation procedures were
used to obtain significance levels empirically and results
were interpreted at a significance level set for p < 0.05.
The transmission disequilibrium test (TDT) was deter-
mined through a McNemar test [81], based on data from
heterozygous parents and the frequency of allelic trans-
mission to affected offspring. The corresponding p-value
(considered at a 0.05 significance level) and OR (95% CI)
were determined.
To reduce the likelihood of commiting a Type I error
due to multiple testing, the Benjamini & Hochberg
procedure [82] was adopted for each set of results
(presented in distinct tables) to control the false dis-
covery rate set at Q = 0.20.Additional files
Additional file 1: Skin prick tests positivity across asthma
persistence and severity subgroups. The table describes the qualitative
(positive vs. negative) and quantitative (<10 mm vs. ≥ 10 mm) reaction
to common allergens in Madeira island (Dermatophagoides pteronyssinus,
Blomia tropicalis, Storage mites, Mix fungi, Indoor fungi, cat and dog)
across overall asthma and asthma severity categories (intermittent,
persistent, mild and moderate-severe).Additional file 2: SNP allelic frequencies for the Madeira reference
set and asthmatics study population. The table describes the allelic
frequencies for SNPs IL4-590, IL4-RP2, IL13-c.144, ADRB2-c.16, ADAM33-V4,
ADAM33-S1c.710, GSDML-236, STAT6-21) across the reference group, overall
asthma and asthma severity categories (intermittent, persistent, mild and
moderate-severe).
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